Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
about
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesPrevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadUsing drug exposure for predicting drug resistance - A data-driven genotypic interpretation toolUniversal amplification, next-generation sequencing, and assembly of HIV-1 genomes.Determination of Phenotypic Resistance Cutoffs From Routine Clinical DataHIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell culturePrevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.Clinical significance of human immunodeficiency virus type 1 replication fitness.Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistanceImpact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.Mechanism of HIV antiretroviral drugs progress toward drug resistance.2014 Update of the drug resistance mutations in HIV-1Pairwise growth competition assay for determining the replication fitness of human immunodeficiency viruses.Precise identification of a human immunodeficiency virus type 1 antigen processing mutant.Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010.Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy.
P2860
Q26851997-B08EE856-16C3-4D1B-9525-A7A2C8A3FE79Q28475698-CE3BCD85-6D5C-46C9-9332-6A43F0C37D72Q28478656-5357EACD-548E-45CF-96ED-F4FC02D3D2BAQ30000270-C877EE58-3819-4E75-A3AE-F989A1CC3446Q30421453-98F5F29A-229C-4312-B85C-F169B7B11071Q31139379-737EA58E-D00C-4D64-B924-FE86638F478DQ33900459-274CD480-7DAC-4B15-BA1C-E9D003425280Q35028707-9257CA4E-67A5-4510-BBD9-4F75C5988895Q35237036-CDBD6024-82E2-4A5E-87BB-D347A4CCA9CEQ35634318-8B4632B6-6314-4F3A-9766-63FFEBEB4D4AQ35784897-A7EC3B7D-F45C-4FFA-A61C-1D992A5ECA74Q36718337-DE7A880C-202D-46A4-9933-C5103D7A5DF7Q36798007-9DAE4DAB-25C6-4F0A-9FFE-4A13E1779C98Q36969857-AAE2BD1C-4CA4-42F5-8BF9-D2BC71F85804Q37277757-07035BAC-20C5-4BD9-B617-150CC21DE13EQ37409900-45860516-2415-442A-B3EB-7B9811F166CBQ37961181-4104C71E-B7CB-4945-92BA-7E5B17C8C3C7Q39498339-70326B50-6AB2-4A86-AF8C-06E8EA6EC5D2Q41213664-5EDA55E7-093F-49D6-B46C-3A187BD1010AQ41928139-E7B384F1-315C-4508-ACA6-FBE92C97B15CQ42269396-F37F59B9-EA18-4B8C-8755-81195C3E40FAQ50787689-E3AD4712-829A-4414-A886-2E8352AB0DC2
P2860
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Transmitted human immunodefici ...... in the presence of zidovudine.
@ast
Transmitted human immunodefici ...... in the presence of zidovudine.
@en
type
label
Transmitted human immunodefici ...... in the presence of zidovudine.
@ast
Transmitted human immunodefici ...... in the presence of zidovudine.
@en
prefLabel
Transmitted human immunodefici ...... in the presence of zidovudine.
@ast
Transmitted human immunodefici ...... in the presence of zidovudine.
@en
P2093
P2860
P1433
P1476
Transmitted human immunodefici ...... in the presence of zidovudine.
@en
P2093
Diane Bennett
Hamish MacInnes
Hillard Weinstock
J Gerardo García-Lerma
P2860
P304
P356
10.1128/JVI.78.14.7545-7552.2004
P407
P577
2004-07-01T00:00:00Z